[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7828 Introduced in House (IH)]
<DOC>
117th CONGRESS
2d Session
H. R. 7828
To amend the Public Health Service Act to shorten the exclusivity
period for brand name biological products from 12 to 5 years.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
May 18, 2022
Ms. Schakowsky (for herself, Mr. Westerman, Mr. Khanna, Mr. Doggett,
Mr. Pocan, Ms. Kaptur, Mr. Garcia of Illinois, and Ms. DeLauro)
introduced the following bill; which was referred to the Committee on
Energy and Commerce
_______________________________________________________________________
A BILL
To amend the Public Health Service Act to shorten the exclusivity
period for brand name biological products from 12 to 5 years.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Price Relief, Innovation, and
Competition for Essential Drugs Act'' or the ``PRICED Act''.
SEC. 2. EXCLUSIVITY PERIOD FOR BRAND NAME BIOLOGICAL PRODUCTS.
(a) In General.--Section 351(k)(7)(A) of the Public Health Service
Act (42 U.S.C. 262(k)(7)(A)) is amended by striking ``12 years'' and
inserting ``5 years''.
(b) Conforming Changes.--Paragraphs (2)(A) and (3)(A) of section
351(m) of the Public Health Service Act (42 U.S.C. 262(m)) is amended
by striking ``12 years'' each place it appears and inserting ``5
years''.
(c) Applicability.--This Act and the amendments made by this Act
apply only with respect to a biological product for which the reference
product (as such term is used in section 351 of the Public Health
Service Act (42 U.S.C. 262)) is licensed under subsection (a) of such
section on or after the date of enactment of this Act.
<all>